Abstract Details

Title Comparison of Discharge Disposition of "Wake-Up Strokes" and Non Wake-Up Strokes

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P03 - (-)

Poster/Presentation
Number 180

Objective

Background BACKGROUND: Wake-up strokes (WUS) are thought to have worse outcomes as compared to strokes occurring while awake, attributable to the inability of WUS patients to undergo thrombolytic therapy. We decided to assess the discharge disposition as a measure of outcome in stroke patients admitted to our center during 2010 and 2011.

Design/Methods DESIGN/METHODS: We retrospectively reviewed records of 438 consecutive patients with ischemic stroke from our center's stroke database. Disposition categories included: 1) discharge to rehabilitation, 2) discharge to home, 3) discharge or return to nursing home or skilled nursing facility and 4) death or hospice. We compared disposition amongst those with WUS versus non-wake up strokes using Chi-square statistics.

Results RESULTS: Among the 438 strokes, there were 53 patients with WUS (about 12% of all ischemic strokes). Those with WUS are more likely to be discharged to rehab than those with non-wake-up strokes (39.6% vs 25.5%), and are less likely to die (5.7% vs 14.8%) or to be discharged to nursing homes or skilled nursing facilities (9.4% vs 15.6%; X2=7.5; df=3; p=0.0579).

Conclusions CONCLUSIONS: Our analysis suggests that patients with wake-up strokes may not experience worse outcomes than those with non-wake up strokes. However, these patients may still benefit from acute interventions.

Authors/Disclosures
Shuchi Chaudhary, MD (Orlando health) PRESENTER	Dr. Chaudhary has nothing to disclose.
Ugur Uygunoglu (Cerrahpasa)	Ugur Uygunoglu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Turkey . The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen Idec/Gen Pharma of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck-Serono of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanovel of Turkey. The institution of Ugur Uygunoglu has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genveon of Turkey.
Ankur Garg, MD (Orlando Neurosurgery)	Dr. Garg has nothing to disclose.
Scott Saucedo, MD (NH Stroke & Neuroscience Specialists)	No disclosure on file
	No disclosure on file
Calin I. Prodan, MD (Univ of Oklahoma - Neurology Dept)	The institution of Dr. Prodan has received research support from US Department of Veterans Affairs (Merit award CX000340).

��ɫ��

��ɫ��